Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
PharmacoEconomics
Published in: PharmacoEconomics 8/2004

01-06-2004 | Commentary

Pharmacogenomics and the Evolution of Healthcare

Is it Time for Cost-Effectiveness Analysis at the Individual Level?

Authors: Dr Mohan V. Bala, Gary A. Zarkin

Published in: PharmacoEconomics | Issue 8/2004

Login to get access

Abstract

The efficacy and toxicity of any given drug can vary substantially from one individual to another. The heterogeneity in individual genetics contributes, in part, to this variability. Pharmacogenomics uses each patient’s individual genetic information to identify the drug with the best efficacy-safety profile for that patient. However, heterogeneity is also present in individuals’ preferences for alternate efficacy-safety profiles. We argue that as healthcare evolves towards individualised drug therapy, preference elicitation and cost-effectiveness analysis should also be performed at the individual level to maximise societal welfare.
Literature
1.
Weinstein IN. Pharmacogenomics: teaching old drugs new tricks. N Engl J Moo 2000 Nov 9; 343 (19): 1408–9CrossRef
2.
3.
Hirth RA, Chernew ME, Miller E, et al. Willingness to pay for a quality-adjusted life year: in search of a standard. Moo Decis Making 2000 Jul-Sep; 20 (3): 332–42
4.
Torrance GW, Seigel JE, Luee BR. Framing and designing the cost-effectiveness analysis. In: Gold MR, Siegel JE, Russell LB, et aI., editors. Cost-effectiveness in health and medicine. New York (NY): Oxford University Press, 1996: 247–75
5.
Sculpher M, Gafni A. Recognizing diversity in public preferences: the use of preference sub-groups in cost-effectiveness analysis. Health Econ 2001 Jun; 10 (4): 317–24PubMedCrossRef
Metadata
Title
Pharmacogenomics and the Evolution of Healthcare
Is it Time for Cost-Effectiveness Analysis at the Individual Level?
Authors
Dr Mohan V. Bala
Gary A. Zarkin
Publication date
01-06-2004
Publisher
Springer International Publishing
Published in
PharmacoEconomics / Issue 8/2004
Print ISSN: 1170-7690
Electronic ISSN: 1179-2027
DOI
https://doi.org/10.2165/00019053-200422080-00002

Other articles of this Issue 8/2004

PharmacoEconomics 8/2004 Go to the issue

Original Research Article

An Economic Evaluation of Fluvastatin used for the Prevention of Cardiac Events Following Successful First Percutaneous Coronary Intervention in the UK

Original Research Article

Psychometric and Utility-Based Measures of Health Status of Asthmatic Patients with Different Disease Control Level

Leading Article

The Role of Cost-Effectiveness Analysis in the Era of Pharmacogenomics

Correspondence

Outcome Measures for Pharmacoeconomics Education

Review Article

Growth Hormone Therapy and Quality of Life in Adults and Children